Recent Updates
Recently added Catalysts
RARE

Ultragenyx Announces Approval of Crysvita (burosumab) in Brazil for the Treatment of X-linked Hypophosphatemia (XLH) in Adults and Children

Tuesday, March 26, 2019 1 min read
Key Takeaway: Ultragenyx Announces Approval of Crysvita (burosumab) in Brazil for the Treatment of X-linked Hypophosphatemia (XLH) in Adults and Children

Full Press Release Details

Ultragenyx Announces Approval of Crysvita (burosumab) in Brazil for the Treatment of X-linked Hypophosphatemia (XLH) in Adults and Children.
Tags: RARE Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Mar 26, 2019